Published in PLoS One on September 08, 2011
Setting Up a Bioluminescence Resonance Energy Transfer High throughput Screening Assay to Search for Protein/Protein Interaction Inhibitors in Mammalian Cells. Front Endocrinol (Lausanne) (2012) 0.93
Role of membrane microdomains in compartmentation of cAMP signaling. PLoS One (2014) 0.89
Biophysical techniques for detection of cAMP and cGMP in living cells. Int J Mol Sci (2013) 0.88
cAMP-PKA inhibition of SK3 channel reduced both Ca2+ entry and cancer cell migration by regulation of SK3-Orai1 complex. Pflugers Arch (2014) 0.82
Identification and validation of modulators of exchange protein activated by cAMP (Epac) activity: structure-function implications for Epac activation and inhibition. J Biol Chem (2014) 0.79
Allosteric inhibition of Epac: computational modeling and experimental validation to identify allosteric sites and inhibitors. J Biol Chem (2014) 0.77
Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹C]MP-10 PET rodent imaging study with ex vivo confirmation. Transl Psychiatry (2014) 0.76
Phosphodiesterase activity is regulated by CC2D1A that is implicated in non-syndromic intellectual disability. Cell Commun Signal (2013) 0.76
PDE2 activity differs in right and left rat ventricular myocardium and differentially regulates β2 adrenoceptor-mediated effects. Exp Biol Med (Maywood) (2014) 0.75
Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev (1995) 5.45
Novel single chain cAMP sensors for receptor-induced signal propagation. J Biol Chem (2004) 5.00
Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science (2002) 4.96
Cyclic nucleotide research -- still expanding after half a century. Nat Rev Mol Cell Biol (2002) 4.16
Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP signaling within discrete subcellular compartments. Proc Natl Acad Sci U S A (2004) 3.31
Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol (2000) 2.62
A genetically encoded, fluorescent indicator for cyclic AMP in living cells. Nat Cell Biol (2000) 2.34
Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci U S A (1999) 2.10
Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway. J Biol Chem (2007) 1.98
Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther (2001) 1.93
Local and long-range reciprocal regulation of cAMP and cGMP in axon/dendrite formation. Science (2010) 1.93
Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci U S A (2000) 1.86
PGE(1) stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases. J Cell Biol (2006) 1.81
Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem (1999) 1.66
Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther (2008) 1.60
Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol (1986) 1.58
Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology (2004) 1.57
Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases. FEBS J (2009) 1.52
The role of type 4 phosphodiesterases in generating microdomains of cAMP: large scale stochastic simulations. PLoS One (2010) 1.34
Compartmentalization of adenylate cyclase and cAMP signalling. Biochem Soc Trans (2005) 1.32
Cyclic AMP second messenger systems. Curr Opin Cell Biol (1991) 1.31
Reinventing the wheel of cyclic AMP: novel mechanisms of cAMP signaling. Ann N Y Acad Sci (2002) 1.26
Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase. Biochemistry (1984) 1.25
cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. Br J Pharmacol (2009) 1.25
Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol (2000) 1.24
The high-affinity cAMP-specific phosphodiesterase 8B controls steroidogenesis in the mouse adrenal gland. Mol Pharmacol (2010) 1.13
Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol Pharmacol (2008) 1.12
Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand. J Biol Chem (1987) 1.10
Dual acylation of PDE2A splice variant 3: targeting to synaptic membranes. J Biol Chem (2009) 0.94
Kinetic properties of Ca2+/calmodulin-dependent phosphodiesterase isoforms dictate intracellular cAMP dynamics in response to elevation of cytosolic Ca2+. Cell Signal (2008) 0.90
Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. Biochem Biophys Res Commun (1997) 0.89
Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity. Biochem J (2009) 0.85
Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science (2004) 4.09
Analysis of deaths related to anesthesia in the period 1996-2004 from closed claims registered by the Danish Patient Insurance Association. Anesthesiology (2007) 3.49
Dwarfism and impaired gut development in insulin-like growth factor II mRNA-binding protein 1-deficient mice. Mol Cell Biol (2004) 2.08
Cytoplasmic trafficking of IGF-II mRNA-binding protein by conserved KH domains. J Cell Sci (2002) 1.38
PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des (2011) 1.37
Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors. Bioorg Med Chem (2010) 0.95
Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor. J Neurosci Methods (2007) 0.95
Comparison of the characteristics of fungal and plant tyrosinases. J Biotechnol (2007) 0.90
Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity. Biochem J (2009) 0.85
Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons. J Neurochem (2009) 0.83
Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors. Bioorg Med Chem Lett (2011) 0.82
Molecular cloning and pharmacological characterization of serotonin 5-HT(3A) receptor subtype in dog. Eur J Pharmacol (2006) 0.79
[Patient handover involves numerous safety risks]. Ugeskr Laeger (2011) 0.78
[Closed claims analysis of deaths related to anesthesia in the period 1996-2004 registered by the Danish Patient Insurance Association]. Ugeskr Laeger (2007) 0.78
Comparison of chromatographic ion-exchange resins VI. Weak anion-exchange resins. J Chromatogr A (2007) 0.76
[Misleading editorial about medical emergency team]. Ugeskr Laeger (2008) 0.75
N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors. Bioorg Med Chem (2013) 0.75
Measurement of cellular beta-site of APP cleaving enzyme 1 activity and its modulation in neuronal assay systems. Anal Biochem (2009) 0.75